1019 / 1068
UNICANCER ACCORD 16 phase II trial
Inclusion: T2
>3cm
-T4 or N+ M0, HIV neg;
Cisplatin 80 mg/m²/d1
Cetuximab 400 mg/m², then weekly 250 mg/m²
5-FU 800/m²/d1-3
RT: 45 Gy in 25 # (IMRT preferred)
Boost
20 Gy in 10 #
2 weeks
break